BioIVT’s human AB serum product line is designed to supplement cell culture media and facilitate cell and gene therapy development.
Human AB serum contains many compounds that are vital for cell growth, including growth factors, vitamins, nutrients, trace elements and transport factors. As a result, human AB serum produces biologically relevant conditions that allow many human cell lines to grow at a faster rate. In addition, a smaller percentage of this serum is required than mixed blood type human serum.
“BioIVT collects blood donations from more than 17,000 donors annually at donor centres located throughout the US and in the UK, so we have a strong, vertically integrated supply chain to support this new product portfolio,” said BioIVT Chief Commercial Officer Alan Findlater. “Furthermore, our recent acquisition of Valley Biomedical Products & Services, Inc. is allowing us to generate larger lots with shorter production times. Valley Biomedical has an excellent track record and has provided the pharmaceutical, biotechnology and academic R&D markets with high quality blood products and cell culture sera for the past 25 years.”
